Aim: We report, herein, three cases of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors. Case 1: A 73-year-old man was diagnosed as having pleomorphic carcinoma of the lung and treated with pembrolizumab alone. However, he showed no response and died 4 months after the initiation of the treatment. Case 2: A 66-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on a combination regimen of pembrolizumab plus carboplatin plus nab-paclitaxel, and a remarkable response was observed. Case 3: A 49-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on pembrolizumab monotherapy as second-line treatment. Eleven months after the treatment initiation, computed tomography revealed the decrease of tumor diameter.
Conclusion: Immune checkpoint inhibitor therapy is expected to improve the prognosis of patients with pleomorphic carcinoma of the lung.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193335 | PMC |
| http://dx.doi.org/10.21873/invivo.12428 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A 70-year-old man was referred to our hospital for an abnormal chest X-ray shadow. A chest CT scan showed a mass shadow with a cavitary lesion in segment 6 of the right lung. One year after radical resection(resection of the lower lobe of the right lung; pT2aN0M0, pStage ⅠB), the patient exhibited enlarged mediastinal lymph nodes and liver metastases, and postoperative recurrence was determined.
View Article and Find Full Text PDFPurpose: There is no current standard treatment regimen for carcinoma ex pleomorphic adenoma (CXPA) of the lacrimal gland. Neoadjuvant intraarterial cytoreductive chemotherapy (IACC) followed by multimodal therapy has achieved good locoregional control in adenoid cystic carcinoma of the lacrimal gland. We reviewed our experience with neoadjuvant IACC followed by multimodal therapy for CXPA of the lacrimal gland.
View Article and Find Full Text PDFSmall intestinal metastasis from primary breast cancer: a case report and review of literature.
Front Immunol
December 2024
Department of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing, China.
Small intestinal metastasis from primary breast cancer remains a rare clinical occurrence. Despite extensive research into its clinicopathological features and treatment options, the specific pathogenesis and optimal management strategies remain incompletely understood. This case report presents a patient with breast cancer that metastasized to the small intestine.
View Article and Find Full Text PDFCorrigendum: Case report: Long remission and survival following immunotherapy in a case of pulmonary pleomorphic carcinoma.
Front Immunol
December 2024
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ;China.
[This corrects the article DOI: 10.3389/fimmu.2024.
View Article and Find Full Text PDFPrimary sarcomatoid carcinoma of the trachea: A case report and literature review.
Medicine (Baltimore)
December 2024
Departments of Medical Oncology, The First People's Hospital of Xiaoshan District, Hangzhou, Zhejiang, China.
Rationale: Primary sarcomatoid carcinoma of the trachea (PSCT) is a rare malignant tumor of the lower respiratory tract. Pathological types of tracheal sarcomatoid carcinoma (TSC)s include pleomorphic carcinomas, giant cell carcinomas, spindle cell carcinomas, pulmonoblastomas, and carcinosarcomas. At present, there are limited reports on PSCT, and pathologists lack sufficient knowledge about it.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!